BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19538891)

  • 1. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
    Xing Y; Zhao JH; Wang TS; Qiao WL; Che WJ
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):129-33. PubMed ID: 19538891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
    Grassetto G; Fornasiero A; Otello D; Bonciarelli G; Rossi E; Nashimben O; Minicozzi AM; Crepaldi G; Pasini F; Facci E; Mandoliti G; Marzola MC; Al-Nahhas A; Rubello D
    Eur J Radiol; 2011 Dec; 80(3):828-33. PubMed ID: 20547020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.
    Kyoto Y; Momose M; Kondo C; Itabashi M; Kameoka S; Kusakabe K
    Ann Nucl Med; 2010 Jun; 24(5):395-401. PubMed ID: 20364373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of (18)F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma.
    Han A; Xue J; Zhu D; Zheng J; Yue J; Yu J
    Cancer Epidemiol; 2011 Oct; 35(5):497-500. PubMed ID: 21296635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of CT attenuation values of focal 18F-FDG avid breast lesions detected on whole-body PET-CT in postoperative breast cancer patients.
    Plaza MJ; Collado-Mesa F; Bokhoor J; Alperin N; Yepes MM
    Breast J; 2014; 20(3):235-42. PubMed ID: 24750508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F-FDG imaging by coincidence circuit SPECT with low-dose CT in preoperative assessment of pulmonary lesions].
    Wang Q; Huang LL; Yue MG; Qin SL; Wang Y; Nie YX; Zhang CQ; Liang TJ; Zhao YM
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):924-7. PubMed ID: 17533745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer.
    Pan HS; Lee SL; Huang LW; Chen YK
    Arch Gynecol Obstet; 2011 Feb; 283(2):335-41. PubMed ID: 20221620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
    Kruse V; Van de Wiele C; Borms M; Maes A; Pottel H; Sathekge M; Cocquyt V
    Nuklearmedizin; 2014 Aug; 53(4):131-8. PubMed ID: 25100557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
    Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
    Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
    Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The compared study in detecting the recurrence and metastases of breast cancer patients post treatment between (18)F-FDG PET/CT and conventional workup].
    Zhang WG; Wang GH; Zhang WD; Fan W; Li J
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(19):1446-9. PubMed ID: 24029564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.